Type I diabetes model
Early reduction of circulating homocysteine levels in Goto-Kakizaki rat, a spontaneous nonobese model of type 2 diabetes
... Abstract Diabetes mellitus is associated with increased risk for cardiovascular disorders, which are major causes of mortality in this ...diseases. Type 2 diabetic patients have higher circulating ...
22
Mechanism of insulin resistance in a rat model of kidney disease and the risk of developing type 2 diabetes
... rat model, there is a correlation between the severity of chronic kidney disease and hyper- glycemia as evaluated by serum fructosamine ...of type 2 diabetes was not observed. Furthermore, in a rat ...
17
Thymic Expression of Insulin-Related Genes in an Animal Model of Autoimmune Type 1 Diabetes
... autoimmune type 1 diabetes, but the origin of immunological self-reactivity specifically oriented against insulin-secreting islet b-cells remains ...of type 1 ...animal model of type 1 ...
7
Resolution of deep venous thrombosis in type 2 diabetes mice model : implication of fibrinolytic and matrix metalloproteinase systems
... Diabetic mice at 1 week (b) and 2 weeks (U) showed more MMP-2 immunostaining in vein wall (W) and thrombus section (T) than control mice (c), Note a reduced expression of MMP-2 was detec[r] ...
136
Longitudinal monitoring of cardiac dysfunction with MRI in a mouse model of obesity and type 2 diabetes
... Obesity consequences include type 2 diabetes and cardi- ovascular diseases. Ectopic fat deposition within certain organs such as heart and liver, have recently been shown to be important independent risk ...
4
MicroRNA-125a is over-expressed in insulin target tissues in a spontaneous rat model of Type 2 Diabetes.
... Our results suggest that increased miR-125a expression may be a characteristic feature of hyperglycaemic GK rats. However, as this study was carried out in rats with long- established T2D phenotypes, it remains unclear ...
12
Vitamin D and type 2 diabetes mellitus: Where do we stand?
... However, one interesting observation of the latter study was the reduction in systolic blood pressure in the treated groups, a change that was not observed in studies by Nag- pal et al. [45] and Jorde and Figenschau [46] ...
8
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
... pharmacokinetics of dulaglutide was well described by a 2-compartment model with first- order absorption. After subcutaneous injection, dulaglutide was slowly absorbed and t max at steady state ranged from 24 to ...
32
Automatic Glycemia Regulation of Type I Diabetes
... 2.11 Conclusions 27 2.10.4 Positivity and state feedback Control As stated earlier and according to the literature of AP studies, input/output constraints of T1DM closed-loop system is mainly taken into account by MPC. ...
209
Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases.
... animal model of spontaneous autoimmune insulin-dependent diabetes ...this model apply to other autoimmune diseases, for which no such diversified data are ...
14
Upregulation of PPARβ/δ Is Associated with Structural and Functional Changes in the Type I Diabetes Rat Diaphragm
... in diabetes depend also on modifications in diaphragmatic arterial blood flow, central nervous system respiratory drive and neuromuscular ...tal model used is thought to mostly reflect type I ...
10
Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?
... minimal model approach, we also reported such acute favorable effect of metformin in a population similar to that of the DPP, ...of diabetes, which limited the statistical power of the analysis (5)— the P ...
4
Pharmacological management of type 2 diabetes: what's new in 2017?
... ago by some people, appears to be a rare event in RCTs, though long-term post-marketing surveillance in real life conditions is still recommended. Beyond their expected side effects related to the increased glucosuria ...
36
DPP-4 inhibitors in the treatment of type 2 diabetes.
... DPP-4 inhibitors are generally well-tolerated, and no increase in adverse events was noted compared to placebo or other comparatives, but again slight differences may exist between the different molecules of this class. ...
27
Type 2 diabetes mellitus and osteoarthritis
... no association between prescribed metformin treatment at baseline and OA outcome during follow up (adjusted HR = 1.02; 95% CI: 0.91, 1.15) [31] . However, in a case-control study performed in Taiwan, patients who have ...
12
Treatment of type 2 diabetes.
... with type 2 diabetes so that the questions why, when and how to prescribe insulin in those individuals remain without definite ...of diabetes and the ultimate goal is to prevent long-term ...with ...
13
Skin autofluorescence predicts cancer in subjects with type 2 diabetes
... Limitations SAF is not a direct measurement of AGE and it may be influenced by other fluorophores in the skin; neverthe- less, SAF does correlate with pentosidine, a common AGE, in skin biopsies. Our population only ...
8
Addition of incretin therapy to metformin in type 2 diabetes.
... butthis result has not been recorded in previous studies (table). 7 Only the 1.8 mg dose of liraglutide was assessed in LEAD-6, 2 in which liraglutide once daily was shown to be superior to 10 µg exenatide twice daily ...
3
‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?
... treatment-resistant diabetes as PPDM despite triple oral therapy, and before the stage of glucose-lowering injectables (insulin and Glucagon-Like Peptide [GLP]-1 receptor agonists) ...cotransporter type 2 ...
3
Caractérisation de la voie d'activation des interférons de type I
... interaction homotypique CARD-CARD avec le premier domaine CARD de RIG- I/MDA5 (Potter et al, 2008). CARDIF joue un rôle essentiel dans la signalisation par les RLRs. Cette protéine est présente dans la membrane ...
323